Lrh-1 modulators
US-2018243245-A1 · Aug 30, 2018 · US
Heterocyclic compound and use thereof
US11440883B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11440883-B2 |
| Application number | US-202016811426-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2020 |
| Priority date | Aug 3, 2017 |
| Publication date | Sep 13, 2022 |
| Grant date | Sep 13, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification,or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
First claim
Opening claim text (preview).
The invention claimed is: 1. N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)ethanesulfonamide or a salt thereof.
Assignees
Inventors
Classifications
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title
Drugs for disorders of the nervous system · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
- C07D211/56Primary
Nitrogen atoms (nitro radicals C07D211/38) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11440883B2 cover?
- The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification,or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
- Who is the assignee on this patent?
- Takeda Pharmaceuticals Co
- What technology area does this patent fall under?
- Primary CPC classification C07D211/56. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).